UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Evaluation and management of postmenopausal hyperandrogenism

Author
Janet E Hall, MD
Section Editors
William F Crowley, Jr, MD
Robert L Barbieri, MD
Deputy Editor
Kathryn A Martin, MD

INTRODUCTION

The presentation of new onset hyperandrogenism is extremely rare in postmenopausal women. In premenopausal women, the most common cause of androgen excess is polycystic ovary syndrome (PCOS). In contrast, when hyperandrogenism develops de novo or progresses in postmenopausal women, it is usually associated with other causes such as ovarian hyperthecosis or an androgen-secreting tumor.

The etiology, clinical presentation, diagnosis, and management of postmenopausal hyperandrogenism are reviewed here. Detailed information on the severe causes of postmenopausal hyperandrogenism and the evaluation of hyperandrogenism in premenopausal women are reviewed separately. (See "Ovarian hyperthecosis" and "Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors" and "Clinical presentation and evaluation of adrenocortical tumors" and "Evaluation of premenopausal women with hirsutism".)

OVERVIEW

Endogenous androgens are produced by the adrenal glands and the ovaries in both pre- and postmenopausal women [1]. With aging, there is a dramatic decrease in adrenal androgens, principally dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), from their peak in early adulthood [2-4]. Changes in ovarian androgen secretion as a function of age and menopause are far less dramatic, with longitudinal studies centered on the final menstrual period showing that total testosterone levels decrease only slightly, with a somewhat greater decrease in sex hormone-binding globulin (SHBG) [2,5]. (See "Overview of androgen deficiency and therapy in women", section on 'Androgen production'.)

Normal androgen levels in postmenopausal women vary depending on the type of assay done and the laboratory in which they are done, but they are generally within or near the following ranges [6-8]:

Total testosterone – 20 to 70 ng/dL (0.5 to 2.8 nmol/L)

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Feb 24 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Burger HG. Androgen production in women. Fertil Steril 2002; 77 Suppl 4:S3.
  2. Burger HG, Dudley EC, Cui J, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000; 85:2832.
  3. Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981; 57:624.
  4. Labrie F, Bélanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997; 82:2396.
  5. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995; 21:103.
  6. Piaditis G, Angellou A, Kontogeorgos G, et al. Ectopic bioactive luteinizing hormone secretion by a pancreatic endocrine tumor, manifested as luteinized granulosa-thecal cell tumor of the ovaries. J Clin Endocrinol Metab 2005; 90:2097.
  7. Cheng V, Doshi KB, Falcone T, Faiman C. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges. Endocr Pract 2011; 17:e21.
  8. Kennedy L, Traub AI, Atkinson AB, Sheridan B. Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor. J Clin Endocrinol Metab 1987; 64:1320.
  9. Outwater EK, Marchetto B, Wagner BJ. Virilizing tumors of the ovary: imaging features. Ultrasound Obstet Gynecol 2000; 15:365.
  10. Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf) 2003; 59:34.
  11. Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003; 88:2634.
  12. Rothman MS, Wierman ME. How should postmenopausal androgen excess be evaluated? Clin Endocrinol (Oxf) 2011; 75:160.
  13. Tagatz GE, Kopher RA, Nagel TC, Okagaki T. The clitoral index: a bioassay of androgenic stimulation. Obstet Gynecol 1979; 54:562.
  14. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.
  15. Rosner W, Vesper H, Endocrine Society, et al. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 2010; 95:4542.
  16. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009; 13:90.
  17. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 2011; 96:623.
  18. Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 2011; 96:2178.
  19. Moran C, Azziz R, Carmina E, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183:1468.
  20. Vigliani MB, Buster JE. Nonclassic 21-hydroxylase deficiency presenting as endometrial hyperplasia with uterine bleeding in a 67-year-old woman. Fertil Steril 2012; 97:950.
  21. Souto SB, Baptista PV, Barreto F, et al. Ovarian intratumoral 21-hydroxylase deficiency in a postmenopausal hirsute woman. Arq Bras Endocrinol Metabol 2012; 56:672.
  22. Rosenfield RL, Cohen RM, Talerman A. Lipid cell tumor of the ovary in reference to adult-onset congenital adrenal hyperplasia and polycystic ovary syndrome. A case report. J Reprod Med 1987; 32:363.
  23. Parker CR Jr, Servy E, McDonough PG, Mahesh VB. In vivo endocrine studies in adrenal rest tumor of ovary. Obstet Gynecol 1974; 44:327.
  24. Kathiresan AS, Carr BR, Attia GR. Virilization from partner's use of topical androgen in a reproductive-aged woman. Am J Obstet Gynecol 2011; 205:e3.
  25. Merhi ZO, Santoro N. Postmenopausal virilization after spousal use of topical androgens. Fertil Steril 2007; 87:976.e13.
  26. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383.
  27. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799.
  28. Braithwaite SS, Erkman-Balis B, Avila TD. Postmenopausal virilization due to ovarian stromal hyperthecosis. J Clin Endocrinol Metab 1978; 46:295.
  29. Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf) 1997; 46:123.
  30. Pugeat M, Raverot G, Plotton I, et al. Androgen-Secreting Adrenal and Ovarian Neoplasms. In: Androgen Excess Disorders in Women: Polycystic Ovary Syndrome and Other Disorders, 2nd ed, Azziz R, Nestler JE, and Dewailly D (Eds), Humana Press, Totowa, New Jersey 2006. p.75.
  31. Larson BA, Vanderlaan WP, Judd HL, McCullough DL. A testosterone-producing adrenal cortical adenoma in an elderly woman. J Clin Endocrinol Metab 1976; 42:882.
  32. Werk EE Jr, Sholiton LE, Kalejs L. Testosterone-secreting adrenal adenoma under gonadotropin control. N Engl J Med 1973; 289:767.
  33. Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.
  34. Sarfati J, Bachelot A, Coussieu C, et al. Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism. Eur J Endocrinol 2011; 165:779.
  35. Bulun SE. Physiology and pathology of the female reproductive axis. In: Williams Textbook of Endocrinology, 12, Melmed S, Polonsky KS, Larsen PR, and Kronenberg HM (Eds), Saunders, Philadelphia 2011. p.581.
  36. Demidov VN, Lipatenkova J, Vikhareva O, et al. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 2008; 31:85.
  37. Faria AM, Perez RV, Marcondes JA, et al. A premenopausal woman with virilization secondary to an ovarian Leydig cell tumor. Nat Rev Endocrinol 2011; 7:240.
  38. Barnes RB, Ehrmann DA. Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor. J Clin Endocrinol Metab 1997; 82:1746.
  39. Shanbhogue AK, Shanbhogue DK, Prasad SR, et al. Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics 2010; 30:903.
  40. Outwater EK, Wagner BJ, Mannion C, et al. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics 1998; 18:1523.
  41. Tanaka YO, Tsunoda H, Kitagawa Y, et al. Functioning ovarian tumors: direct and indirect findings at MR imaging. Radiographics 2004; 24 Suppl 1:S147.
  42. Sakamoto K, Fujimitsu R, Ida M, et al. MR diagnosis of steroid cell tumor of the ovary: value of chemical shift imaging. Magn Reson Med Sci 2009; 8:193.
  43. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 2006; 30:277.
  44. Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med 2006; 130:1725.
  45. Cavlan D, Bharwani N, Grossman A. Androgen- and estrogen-secreting adrenal cancers. Semin Oncol 2010; 37:638.
  46. Cordera F, Grant C, van Heerden J, et al. Androgen-secreting adrenal tumors. Surgery 2003; 134:874.
  47. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics 2009; 29:1333.
  48. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21:995.
  49. Dickerson RD, Putman MJ, Black ME, et al. Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil Steril 2005; 84:218.
  50. Petersons CJ, Burt MG. The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern Med J 2011; 41:69.
  51. Alpañés M, González-Casbas JM, Sánchez J, et al. Management of postmenopausal virilization. J Clin Endocrinol Metab 2012; 97:2584.
  52. Ehrmann DA, Rosenfield RL, Barnes RB, et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327:157.
  53. Krug E, Berga SL. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet Gynecol 2002; 99:893.
  54. Rousset P, Gompel A, Christin-Maitre S, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol 2008; 32:694.
  55. Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996; 7:38.
  56. Goswamy RK, Campbell S, Royston JP, et al. Ovarian size in postmenopausal women. Br J Obstet Gynaecol 1988; 95:795.
  57. Rosenkrantz AB, Popiolek D, Bennett GL, Hecht EM. Magnetic resonance imaging appearance of ovarian stromal hyperplasia and ovarian hyperthecosis. J Comput Assist Tomogr 2009; 33:912.
  58. Nakashima N, Young RH, Scully RE. Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature. Arch Pathol Lab Med 1984; 108:786.
  59. Wu DH, McMurtrie DG, Hirsch SD, Johnston CM. Postmenopausal hyperandrogenism caused by a benign cystic teratoma: a case report. J Reprod Med 2008; 53:141.
  60. Bachelot A, Meduri G, Baudin E, et al. Hyperandrogenism in a postmenopausal woman presenting with a metastatic ileum endocrine tumor. Fertil Steril 2004; 81:675.
  61. Hornung M, Vogel P, Schubert T, et al. A case of virilization induced by a Krukenberg tumor from gastric cancer. World J Surg Oncol 2008; 6:19.
  62. Akishima-Fukasawa Y, Yoshihara A, Ishikawa Y, et al. Malignant adrenal rest tumor of the retroperitoneum producing adrenocortical steroids. Endocr Pathol 2011; 22:112.
  63. Damodaran S, Mahmood T, Nawroz I, Swaminathan K. Ovarian stromal hyperplasia and hyperthecosis: an unusual case of post-menopausal hirsutism. Eur J Obstet Gynecol Reprod Biol 2011; 158:114.
  64. Stearns HC, Sneeden VD, Fearl JD. A clinical and pathologic review of ovarian stromal hyperplasia and its possible relationship to common diseases of the female reproductive system. Am J Obstet Gynecol 1974; 119:375.
  65. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130:270.
  66. Tseng L, Mazella J, Funt MI, et al. Preliminary studies of aromatase in human neoplastic endometrium. Obstet Gynecol 1984; 63:150.
  67. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38:476.
  68. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88:1127.
  69. Austin H, Austin JM Jr, Partridge EE, et al. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51:568.
  70. Agorastos T, Argyriadis N, Fraggidis G, et al. Postmenopausal virilization due to ovarian hyperthecosis. Arch Gynecol Obstet 1995; 256:209.
  71. Efstathiadou Z, Tsatsoulis A. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist. Fertil Steril 2001; 75:59.
  72. Vollaard ES, van Beek AP, Verburg FA, et al. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab 2011; 96:1197.
  73. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.